Martin Dreyling, MD, Talks TRIANGLE Trial, MCL Management

By Blood Cancer Talks - Last Updated: August 1, 2023

Lead author of the TRIANGLE study, Dr. Dreyling, who is Associate Professor of Medicine at the University of Munich, leads listeners through the management of mantle cell lymphoma (MCL) in newly diagnosed patients, in this episode of “Blood Cancer Talks.”

Dr. Dreyling also answers questions on treating patients without access to upfront ibrutinib access as per the TRIANGLE trial, if allogeneic transplant has a role in MCL, and more.

ASH 2023 Lymphoma Recap with Toby Eyre, MD

Michael Dickinson, MBBS, on Bispecific Antibodies Across Lymphomas

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Martin Dreyling, MD, Talks TRIANGLE Trial, MCL Management

Related